Cirrus Dx received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) to perform SARS-COVID-19 testing.
CirrusDx validated and will commercialize the Allplex™ 2019-nCoV Assay, a real-time Reverse Transcriptase PCR test developed by Seegene, a South Korea-based company involved in multiplex molecular diagnostics. The Seegene test can simultaneously detect three different genes (N, E and RdRP) of SARS-CoV-2, the virus responsible for COVID-19.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"As an infectious disease laboratory in the Washington D.C. area, there is a responsibility to serve the community at large," said Kyle Armantrout, Managing Director at CirrusDx. "Partnering with Seegene to bring Allplex™ 2019-nCoV Assay to high risk communities such as long-term care centers, and healthcare providers on the front lines, is mission critical for our organizations."
The Allplex™ 2019-nCoV Assay test will be performed in the CirrusDx CLIA High Complexity Laboratory with results reporting to clinicians within 24 hours of sample receipt.